Growth & profitability
- Revenue has grown 19.1% per year over the past 5 years.
- Operating margin has expanded, at -154.5% in the latest year.
Financial health
- Total debt has grown slower than revenue (-22.7% vs 19.1% per year).
STRO Financials Sutro Biopharma, Inc.
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $102M | -$191M | 0.0% | -154.5% | — | — | $58M |
| 2024 | $62M | -$227M | 0.0% | -384.3% | — | — | $190M |
| 2023 | $154M | -$107M | 0.0% | -58.1% | — | $4M | $69M |
| 2022 | $68M | -$119M | 0.0% | -190.3% | — | $16M | $47M |
| 2021 | $62M | -$106M | 0.0% | -159.2% | — | $25M | $30M |
| 2020 | $43M | -$32M | 0.0% | -166.3% | — | $25M | $206M |
| 2019 | $43M | -$119M | 0.0% | -129.8% | — | $9M | $5M |
| 2018 | $38M | -$35M | 0.0% | -96.9% | $11M | $15M | $125M |
| 2017 | $52M | -$20M | 0.0% | -37.2% | -$40M | — | $22M |
| 2016 | — | $2M | — | — | -$18M | — | $12M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $15M | -$38M | 0.0% | -204.2% | — | — | $74M |
| Dec '25 | $12M | -$47M | 0.0% | -326.7% | — | — | $58M |
| Sep '25 | $10M | -$57M | 0.0% | -499.9% | — | — | $66M |
| Jun '25 | $64M | -$11M | 0.0% | -5.2% | — | — | $64M |
| Mar '25 | $17M | -$76M | 0.0% | -393.8% | — | — | $106M |
| Dec '24 | $15M | -$72M | 0.0% | -440.7% | — | — | $190M |
| Sep '24 | $9M | -$49M | 0.0% | -797.2% | — | — | $175M |
| Jun '24 | $26M | -$48M | 0.0% | -189.4% | — | — | $91M |
| Mar '24 | $13M | -$58M | 0.0% | -435.0% | — | — | $65M |
| Dec '23 | $114M | $31M | 0.0% | 37.9% | — | $4M | $69M |
| Sep '23 | $17M | -$49M | 0.0% | -260.1% | — | — | $82M |
| Jun '23 | $10M | -$39M | 0.0% | -443.5% | — | — | $235M |
| Mar '23 | $13M | -$50M | 0.0% | -333.3% | — | — | $62M |
| Dec '22 | $9M | -$35M | 0.0% | -570.2% | — | $16M | $47M |
| Sep '22 | $25M | -$19M | 0.0% | -84.3% | — | $7M | $97M |
| Jun '22 | $28M | -$26M | 0.0% | -69.0% | — | $10M | $79M |
| Mar '22 | $6M | -$39M | 0.0% | -663.6% | — | $13M | $29M |
| Dec '21 | $11M | -$38M | 0.0% | -328.9% | — | $25M | $30M |
| Sep '21 | $9M | -$31M | 0.0% | -407.1% | — | $19M | $31M |
| Jun '21 | $28M | -$6M | 0.0% | -35.0% | — | $22M | $56M |
Valuation over time
How the market has priced STRO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 1.1× (Mar '23) to 4.8× (Jun '26).
P/S
Frequently asked questions
Is STRO growing its revenue and profit?
Over the past 5 years, Sutro Biopharma, Inc.'s revenue has grown 19.1% per year. These are computed facts, not advice.
How much debt does STRO have?
As of FY2025, Sutro Biopharma, Inc. reported — of total debt against $58M of cash.
What is STRO's profit margin?
In FY2025, gross margin was —, operating margin -154.5%, and net margin -186.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.